- Market Capitalization, $K 6,460,674
- Shares Outstanding, K 191,314
- Annual Sales, $ 206,900 K
- Annual Income, $ 50,210 K
- 60-Month Beta N/A
- Price/Sales 20.27
- Price/Cash Flow N/A
- Price/Book 7.48
|Period||Period Low||Period High||Performance|
| || |
-16.54 (-32.88%)since 04/14/22
| || |
-23.61 (-41.15%)since 02/17/22
DOCS earnings call for the period ending March 31, 2022.
Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.
Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.
Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.
Doximity (DOCS) closed the most recent trading day at $42.54, moving -1.76% from the previous trading session.
If you have a long investing time horizon, these strong performers could deliver massive gains.
Doximity has the potential to be a great investment over the long term.
These companies strike the right balance of potential and leadership, which could help them achieve strong returns over the next decade.
Doximity's revolutionary business model creates a compelling competitive advantage for the company.
Doximity (DOCS) closed at $48.83 in the latest trading session, marking a +0.04% move from the prior day.
|3rd Resistance Point||39.16|
|2nd Resistance Point||37.15|
|1st Resistance Point||35.46|
|1st Support Level||31.76|
|2nd Support Level||29.75|
|3rd Support Level||28.06|